## ISRG: Intuitive Surgical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.3% below STRENGTH zone (4.0-10.0%); PEG 3.36 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($533.58)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Intuitive Surgical (ISRG) Stock After Hours: What Happened on Dec. 15, 2025—and What to Watch Before Tuesday’s Open**
- Source: ts2.tech | 20251216T013857 | Somewhat-Bullish | Relevance: 100%
- Intuitive Surgical (ISRG) saw a rebound on Monday, December 15, 2025, closing up 3.17% at $559.52, but then experienced a modest dip in after-hours trading. A key development was an insider Form 4 filing related to a planned sale of shares by an executive, which is unlikely to impact long-term fundamentals but could influence short-term sentiment. Heading into Tuesday, investors should also monitor significant U.S. economic data releases, particularly the rescheduled retail sales figures.

**2. Intuitive Surgical (ISRG) stock: What to know before the U.S. market opens on Dec. 15, 2025**
- Source: ts2.tech | 20251214T221221 | Neutral | Relevance: 100%
- This article provides a comprehensive overview of key factors influencing Intuitive Surgical (ISRG) stock before the market opens on December 15, 2025. It highlights recent FDA clearances for its da Vinci SP system, increasing competition from Medtronic and Johnson & Johnson, Q3 2025 financial performance, ongoing product momentum, and analyst forecasts, all while considering the stock's premium valuation.

**3. Nilsine Partners LLC Sells 7,507 Shares of Intuitive Surgical, Inc. $ISRG**
- Source: MarketBeat | 20251216T130533 | Neutral | Relevance: 100%
- Nilsine Partners LLC significantly reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 51.8% in Q3, selling 7,507 shares and holding 6,986 shares valued at $3.12 million. Insider selling also occurred, with executives selling 114,007 shares collectively worth $63.53 million, leaving insiders with 0.70% ownership. Despite this, Intuitive Surgical reported strong quarterly earnings, beating analyst expectations, and maintains a "Moderate Buy" consensus with an average target price of $608.79.

**4. With 0.06% One-year Returns, Institutional Owners May Ignore Intuitive Surgical, Inc.'s (NASDAQ:ISRG) 4.3% Stock Price Decline**
- Source: 富途牛牛 | 20251215T210835 | Neutral | Relevance: 100%
- Institutional investors, holding 86% of Intuitive Surgical, Inc. (NASDAQ:ISRG), have experienced negligible one-year returns (0.06%), which might make them less concerned about the recent 4.3% stock price drop. The Vanguard Group is the largest shareholder with 9.5%, while insiders own less than 1% but represent a significant dollar value. The general public holds a 14% stake, indicating a widely disseminated ownership structure without a dominant individual shareholder among the top 25, who collectively own less than half the company.

**5. Intuitive Surgical (ISRG) Stock News Today: What’s Driving Shares, Latest Analyst Forecasts, and Key Catalysts for 2026 (Dec. 15, 2025)**
- Source: ts2.tech | 20251215T202816 | Bullish | Relevance: 100%
- Intuitive Surgical (ISRG) stock gained approximately 3% on December 15, 2025, driven by institutional ownership updates, bullish options activity, and ETF inflows. While analysts maintain a "Moderate Buy" to "Strong Buy" consensus with price targets in the low-$600s, the valuation remains a point of debate following a recent Citigroup downgrade. The company's long-term prospects are supported by strong procedure growth, expanding product indications, and international expansion, but risks include its high valuation and capital spending cycles.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $635 | $650 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($2.31M) |
| Sells | 14 ($32.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.8%)
- Blackrock Inc.: 8.8% (+0.1%)
- State Street Corpora: 4.3% (-0.1%)
- Price (T.Rowe) Assoc: 3.6% (-4.4%)
- Geode Capital Manage: 2.3% (+1.0%)

### Key Risks

1. Heavy insider selling: $32M sold (14 transactions in 90 days).
2. Valuation stretched: PEG 3.4x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.36 signals overvaluation risk, limited margin of safety. Forward P/E 57.4x stretched relative to 13% growth. Quality metrics strong (margin 29%). Balance sheet: strong liquidity (4.7x), low leverage (D/E 0.14). Analyst sentiment negative (1 target cuts vs 0 raises). Insider selling cluster ($32.3M in 90 days), potential headwind. Institutional flow bearish (4 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $200.6B |
| Beta | 1.69 |
| 52W Range | $425.00 - $616.00 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.36 |
| Forward P/E | 57.4 |
| Current P/E | 64.7 |
| YoY Growth | 12.7% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -3.3% to -0.3% (+3.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.3pp (needs >4.0% for momentum thesis). MRS_5 turning positive (2.8%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-4.80), momentum weakening. RSI neutral at 53. Elevated volume (1.3x 20MA), institutional activity likely. OFD pattern: +FTH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.26% (CS: 33) | Neutral |
| RSI_14 | 53.3 | Neutral |
| MACD Histogram | -4.80 | Bearish |
| vs SMA20 | 0.995x | Below |
| vs SMA50 | 1.057x | Above |
| vs SMA200 | 1.101x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $559.52
- **Stop Loss:** $533.58 (4.6% risk)
- **Target:** $585.46 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 46
- **Position Value:** $25,737.92
- **Portfolio %:** 25.74%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-01-22 (Est: $2.24)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.99 | $2.40 | +20.7% |
| 2025Q2 | $1.92 | $2.19 | +14.1% |
| 2025Q1 | $1.73 | $1.81 | +4.4% |
| 2024Q4 | $1.79 | $2.21 | +23.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*